Alto Neuroscience, Inc. (ANRO NYSE) stock market data APIs
$15.2514
-0.81(-5.3%)
as of February 6, 2026
Try our APIs with
free plan!
Alto Neuroscience, Inc. Financial Data Overview
Price chart is built with
Anychart
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Prev. Close
15.2514
Open
14.437
High
15.398
Low
13.8021
52 wk Range
1.6-20.908
Market Cap
438 M
Shares Outstanding
31 066 K
EPS
-0.52
Beta
2.851
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alto Neuroscience, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alto Neuroscience, Inc. data using free add-ons & libraries
Get Alto Neuroscience, Inc. Fundamental Data
Alto Neuroscience, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -65 632 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alto Neuroscience, Inc. News
New
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Alto Neuroscience, Inc. (NYSE: ANRO), Atkore Inc. ...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Alto Neuroscience, Inc. (NYSE: ANRO), Atkore Inc. ...
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
NEW YORK, Nov. 11, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market ins...
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies. Many pharma giants, like Am...
Get Alto Neuroscience, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
